Cadian Capital Management LP Grows Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Cadian Capital Management LP lifted its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 14.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,927,027 shares of the company's stock after purchasing an additional 609,021 shares during the quarter. Cryoport comprises about 2.2% of Cadian Capital Management LP's portfolio, making the stock its 16th biggest position. Cadian Capital Management LP owned approximately 9.97% of Cryoport worth $38,332,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company's stock valued at $660,000 after purchasing an additional 59,582 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Cryoport by 44.8% in the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock valued at $1,142,000 after acquiring an additional 45,430 shares during the period. Rhumbline Advisers raised its stake in Cryoport by 2.9% in the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after acquiring an additional 1,764 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Cryoport by 1,464.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock worth $2,475,000 after acquiring an additional 285,726 shares during the period. Finally, Thrivent Financial for Lutherans purchased a new position in shares of Cryoport in the fourth quarter worth about $299,000. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Roth Mkm reissued a "buy" rating and set a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. Morgan Stanley dropped their target price on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday. Guggenheim reaffirmed a "buy" rating and set a $10.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. UBS Group boosted their target price on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Cryoport in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $11.00.

Insider Activity

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 19,830 shares of company stock valued at $118,353. 10.10% of the stock is currently owned by company insiders.

Cryoport Price Performance

CYRX traded up $0.09 on Friday, hitting $7.07. 549,895 shares of the company's stock were exchanged, compared to its average volume of 543,452. The firm has a 50-day moving average price of $5.84 and a 200-day moving average price of $6.86. The stock has a market cap of $354.47 million, a price-to-earnings ratio of -2.09 and a beta of 1.92. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $14.21.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. As a group, equities analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.